| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16,7 k € | -55.6% | 37,5 k € | 0.0% | 37,5 k € | +19.1% | 31,5 k € | -12.1% | 35,8 k € | -35.6% | 55,6 k € | -2.2% | 56,9 k € | -8.9% | 62,4 k € | +12.2% | 55,6 k € | 0.0% | 55,6 k € | 0.0% | 55,6 k € | |
| Gross margin | 9,6 k € | -64.8% | 27,4 k € | +16.8% | 23,4 k € | +3.2% | 22,7 k € | -22.1% | 29,1 k € | -33.1% | 43,6 k € | -10.9% | 48,9 k € | -3.0% | 50,4 k € | +0.4% | 50,2 k € | -5.0% | 52,8 k € | -2.1% | 54,0 k € | |
| EBITDA | 9,2 k € | -65.7% | 27,0 k € | +17.2% | 23,0 k € | +3.0% | 22,3 k € | -20.3% | 28,0 k € | -35.2% | 43,2 k € | -10.9% | 48,5 k € | -3.0% | 50,0 k € | +0.4% | 49,8 k € | -5.0% | 52,5 k € | -2.2% | 53,6 k € | |
| Operating profit | 9,2 k € | +154.6% | -16,9 k € | +19.0% | -20,9 k € | +3.1% | -21,6 k € | -35.8% | -15,9 k € | -2214.4% | -686,0 € | -115.9% | 4,3 k € | -25.9% | 5,8 k € | +3.4% | 5,6 k € | -31.9% | 8,2 k € | -12.3% | 9,4 k € | |
| Profit/loss | 9,2 k € | +154.3% | -17,0 k € | +28.8% | -23,8 k € | -6.3% | -22,4 k € | -17.4% | -19,1 k € | -447.8% | -3,5 k € | -2740.9% | 132,0 € | -89.0% | 1,2 k € | +605.9% | 170,0 € | -89.6% | 1,6 k € | +622.0% | 227,0 € | |
| Equity | -67,0 k € | +12.1% | -76,2 k € | -28.6% | -59,2 k € | -67.3% | -35,4 k € | -172.2% | -13,0 k € | -313.8% | 6,1 k € | -36.4% | 9,6 k € | +1.4% | 9,4 k € | +14.6% | 8,2 k € | +2.1% | 8,1 k € | +25.5% | 6,4 k € | |
| Total assets | 105,6 k € | -7.3% | 114,0 k € | -22.4% | 146,9 k € | -16.4% | 175,8 k € | -16.6% | 210,9 k € | -17.5% | 255,7 k € | +13.6% | 225,2 k € | -16.9% | 270,9 k € | -18.7% | 333,5 k € | -24.9% | 444,2 k € | -7.6% | 480,6 k € | |
| Cash | 277,0 € | +1878.6% | 14,0 € | -89.9% | 138,0 € | -44.6% | 249,0 € | 0,0 € | -100.0% | 377,0 € | +179.3% | 135,0 € | -70.4% | 456,0 € | -4.8% | 479,0 € | -53.1% | 1,0 k € | +121.7% | 461,0 € | ||
| Debts | 172,6 k € | -9.3% | 190,2 k € | -7.7% | 206,1 k € | -2.4% | 211,2 k € | -5.7% | 223,9 k € | -10.3% | 249,6 k € | +15.8% | 215,6 k € | -17.6% | 261,5 k € | -19.6% | 325,2 k € | -25.4% | 436,1 k € | -8.0% | 474,1 k € | |
Source: Belgian Official Gazette
Private company with limited liability · Lubbeek · incorporated on 22/01/2014
Private company with limited liability with a balanced profile. Cash position rising (+1878.6%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Beisol Pharma Poederlee is a Private company with limited liability incorporated in 2014. Its main activity is: Leasing of intellectual property and similar products, except copyrighted works. Its registered office is in Lubbeek.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.